LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

72.11 -2.97

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

71.64

Max

74.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-100M -229M
Pardavimai	46M 203M
Pelno marža	-112.808
Darbuotojai	1,402
EBITDA	4.7B 4.6B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+30.91% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-2B 12B
Ankstesnė atidarymo kaina	75.08
Ankstesnė uždarymo kaina	72.11

Naujienos nuotaikos

By Acuity

50%

158 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-27 17:33; UTC

Svarbiausios naujienos

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026-03-27 17:00; UTC

Svarbiausios naujienos

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026-03-27 16:03; UTC

Svarbiausios naujienos

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026-03-27 14:50; UTC

Pagrindinės rinkos jėgos

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

2026-03-27 14:37; UTC

Įsigijimai, susijungimai, perėmimai

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

2026-03-27 14:29; UTC

Svarbiausios naujienos

EU Finance Ministers Tally Economic Hit of Iran War -- Update

2026-03-27 14:16; UTC

Svarbiausios naujienos

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

2026-03-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 19:16; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026-03-27 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026-03-27 19:04; UTC

Rinkos pokalbiai

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026-03-27 19:03; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 19:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026-03-27 18:12; UTC

Rinkos pokalbiai

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026-03-27 17:36; UTC

Svarbiausios naujienos

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026-03-27 17:34; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026-03-27 17:29; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026-03-27 16:38; UTC

Rinkos pokalbiai

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026-03-27 16:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026-03-27 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 15:43; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin Says Iran War Raising Economic Uncertainty

2026-03-27 14:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

2026-03-27 14:26; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

2026-03-27 14:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 14:14; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

30.91% į viršų

12 mėnesių prognozė

Vidutinis 97.19 USD 30.91%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

158 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.